Clinical Trial Update: Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 2/Phase 3 study of nimotuzumab combined with GX as postoperative adjuvant therapy in pancreatic cancer, not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• GX
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Pancreatic Cancer | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING